We achieve direct therapeutic targets such as APP, MAPT (also known as Tau), PPARG70, MMP9, MMP271,72, and HTR2A (also known as 5-HT2A), GRIN2B (glutamate ionotropic receptor NMDA type subunit 2B), and GRIA1 (glutamate ionotropic receptor AMPA type subunit 1)73 or downstream potential targets such as PTGS274 or NOS275 that are associated with neuroinflammation or various diseases of nervous system. This evidence concerns the gene MMP9 and nervous system disorder.